Article
TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.
Blood - 6 Oct 2011
Chou Wen-Chien, Chou Sheng-Chieh, Liu Chieh-Yu, Chen Chien-Yuan, Hou Hsin-An, Kuo Yuan-Yeh, Lee Ming-Cheng, Ko Bor-Sheng, Tang Jih-Luh, Yao Ming, Tsay Woei, Wu Shang-Ju, Huang Shang-Yi, Hsu Szu-Chun, Chen Yao-Chang, Chang Yi-Chang, Kuo Yi-Yi, Kuo Kuan-Ting, Lee Fen-Yu, Liu Ming-Chi, Liu Chia-Wen, Tseng Mei-Hsuan, Huang Chi-Fei, Tien Hwei-Fang
Abstract excerpt
The studies concerning clinical implications of TET2 mutation in patients with primary acute myeloid leukemia (AML) are scarce. We analyzed TET2 mutation in 486 adult patients with primary AML. TET2 mutation occurred in 13.2% of our patients and was closely associated with older age, higher white blood cell and blast counts, lower platelet numbers, normal karyotype, intermediate-risk cytogenetics, isolated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.